Identification of matrine as a promising novel drug for hepatic steatosis and glucose intolerance with HSP72 as an upstream target

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4303-4318

  Zeng, Xiao Yi ^a   Wang, Hao ^a   Bai, Fang ^b   Zhou, Xiu ^a   Li, Song Pei ^a   Ren, Lu Ping ^a   Sun, Ruo Qiong ^a   Xue, Charlie C L ^a   Jiang, Hua Liang ^b   Hu, Li Hong ^b   Ye, Ji Ming ^a  

^a RMIT UNIVERSITY   (Australia)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GANETESPIB; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; INSULIN; MATRINE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; ALKALOID; QUINOLIZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CALORIC INTAKE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENERGY EXPENDITURE; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIVE PROTEIN LEVEL; LIVER LEVEL; LIVER TRIGLYCERIDE LEVEL; MALE; MITOCHONDRIAL RESPIRATION; MOLECULAR DOCKING; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN CONTENT; ADVERSE EFFECTS; AGONISTS; ANIMAL; C57BL MOUSE; DRUG DELIVERY SYSTEM; LIPID DIET; METABOLISM; TRENDS;

ALKALOIDS; ANIMALS; DIET, HIGH-FAT; DRUG DELIVERY SYSTEMS; FATTY LIVER; GLUCOSE INTOLERANCE; HSP72 HEAT-SHOCK PROTEINS; MALE; MICE; MICE, INBRED C57BL; QUINOLIZINES;

EID: 84938718503     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13209     Document Type: Article

References (63)

1. Anckar J, Sistonen L, (2011). Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu Rev Biochem 80: 1089-1115.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol 170: 1706-1796.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
5. Anderson I, Low JS, Weston S, Weinberger M, Zhyvoloup A, Labokha AA, et al. (2014). Heat shock protein 90 controls HIV-1 reactivation from latency. Proc Natl Acad Sci U S A 111: E1528-E1537.
6. Bugianesi E, Salamone F, Negro F, (2012). The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 56 (Suppl. 1): S56-S65.
7. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. (2011). Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140: 1071-1083.
8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609.
9. Chan SM, Sun RQ, Zeng XY, Choong ZH, Wang H, Watt MJ, et al. (2013). Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 62: 2095-2105.
10. China Food and Drug Administration (2014). Domestic Drugs Database [Online]. Available at: http://eng.sfda.gov.cn/ (accessed 9/1/2014).
11. Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, et al. (2008). HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A 105: 1739-1744.
12. Cohen JC, Horton JD, Hobbs HH, (2011). Human fatty liver disease: old questions and new insights. Science 332: 1519-1523.
13. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G, (1998). The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79: 129-168.
14. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, et al. (2009). Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106: 15430-15435.
15. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. (2012). FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 26: 271-281.
16. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
17. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, et al. (2013). Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 19: 1649-1654.
18. Gao G, Law FC, (2009). Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA. Drug Metab Dispos 37: 884-891.
19. Gupte AA, Bomhoff GL, Swerdlow RH, Geiger PC, (2009). Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet. Diabetes 58: 567-578.
20. Hardie DG, (2013). AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62: 2164-2172.
21. He B, Meng YH, Mivechi NF, (1998). Glycogen synthase kinase 3beta and extracellular signal-regulated kinase inactivate heat shock transcription factor 1 by facilitating the disappearance of transcriptionally active granules after heat shock. Mol Cell Biol 18: 6624-6633.
22. Hu J, Seeger C, (1996). Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci U S A 93: 1060-1064.
23. International Diabetes Federation (2013). IDF Diabetes Atlas, 6th edn. International Diabetes Federation: Brussels, Belgium.
24. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. (2012). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
27. Kurucz I, Morva A, Vaag A, Eriksson KF, Huang X, Groop L, et al. (2002). Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance. Diabetes 51: 1102-1109.
28. Liang CZ, Zhang JK, Shi Z, Liu B, Shen CQ, Tao HM, (2012). Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother Pharmacol 69: 317-331.
29. Liossis SN, Ding XZ, Kiang JG, Tsokos GC, (1997). Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. J Immunol 158: 5668-5675.
30. Liu J, Zhu M, Shi R, Yang M, (2003). Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. Am J Chin Med 31: 337-354.
31. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Molero JC, Waring SG, Cooper A, Turner N, Laybutt R, Cooney GJ, et al. (2006). Casitas b-lineage lymphoma-deficient mice are protected against high-fat diet-induced obesity and insulin resistance. Diabetes 55: 708-715.
33. Muoio DM, (2010). Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? Biochim Biophys Acta 1801: 281-288.
34. Musso G, Cassader M, Rosina F, Gambino R, (2012). Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55: 885-904.
35. Neckers L, Workman P, (2012). Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
36. Nguyen MT, Csermely P, Soti C, (2013). Hsp90 chaperones PPARgamma and regulates differentiation and survival of 3T3-L1 adipocytes. Cell Death Differ 20: 1654-1663.
37. Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, et al. (2006). Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 25: 5015-5025.
38. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
39. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI, (2005). Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54: 603-608.
40. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH, (1997). Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90: 65-75.
41. Putics A, Vegh EM, Csermely P, Soti C, (2008). Resveratrol induces the heat-shock response and protects human cells from severe heat stress. Antioxid Redox Signal 10: 65-75.
42. Rena G, Pearson ER, Sakamoto K, (2013). Molecular mechanism of action of metformin: old or new insights? Diabetologia 56: 1898-1906.
43. Sagan SM, Rouleau Y, Leggiadro C, Supekova L, Schultz PG, Su AI, et al. (2006). The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication. Biochem Cell Biol 84: 67-79.
44. Samuel VT, Shulman GI, (2012). Mechanisms for insulin resistance: common threads and missing links. Cell 148: 852-871.
45. Samuel VT, Petersen KF, Shulman GI, (2010). Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277.
46. Shelley J, Cholleti A, Frye L, Greenwood J, Timlin M, Uchimaya M, (2007). Epik: a software program for pK a prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21: 681-691.
47. Shi LJ, Shi L, Song GY, Zhang HF, Hu ZJ, Wang C, et al. (2013). Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (PPARalpha). Eur J Pharmacol 714: 89-95.
48. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P, (2005). Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146: 769-780.
49. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP, (1997). Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89: 239-250.
50. Strittmatter SM, (2014). Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat Med 20: 590-591.
51. Syed GH, Amako Y, Siddiqui A, (2010). Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21: 33-40.
52. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, et al. (2008). Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 15: 263-273.
53. Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, et al. (2014). Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-beta signalling to prevent fibrosis. Ann Rheum Dis 73: 1215-1222.
54. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. (2008). Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57: 1414-1418.
55. Wang S, Wang G, Li X, Sun J, Ma R, Sheng L, (2005). Simultaneous determination of oxymatrine and its active metabolite matrine in dog plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 817: 319-325.
56. Winklhofer KF, Reintjes A, Hoener MC, Voellmy R, Tatzelt J, (2001). Geldanamycin restores a defective heat shock response in vivo. J Biol Chem 276: 45160-45167.
57. Yang F, Chen WL, Zheng MZ, Yu GW, Xu HJ, Shen YL, et al. (2011). Heat shock protein 90 mediates anti-apoptotic effect of diazoxide by preventing the cleavage of Bid in hypothermic preservation rat hearts. J Heart Lung Transplant 30: 928-934.
58. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW, (2001). Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50: 411-417.
59. Zeng XY, Zhou X, Xu J, Chan SM, Xue CL, Molero JC, et al. (2012a). Screening for the efficacy on lipid accumulation in 3T3-L1 cells is an effective tool for the identification of new anti-diabetic compounds. Biochem Pharmacol 84: 830-837.
60. Zeng XY, Wang YP, Cantley J, Iseli TJ, Molero JC, Hegarty BD, et al. (2012b). Oleanolic acid reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type-2 diabetic mice. PLoS ONE 7: e42115.
61. Zhang B, Liu ZY, Li YY, Luo Y, Liu ML, Dong HY, et al. (2011). Anti-inflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci 44: 573-579.
62. Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, et al. (2001). Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin 22: 183-186.
63. Zhou H, Xu M, Gao Y, Deng Z, Cao H, Zhang W, et al. (2014). Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factor. Mol Cancer 13: 59.